Boston Life Sciences, Inc. Elects William L.S. Guinness to Its Board of Directors
July 27 2006 - 9:31AM
PR Newswire (US)
HOPKINTON, Mass., July 27 /PRNewswire-FirstCall/ -- Boston Life
Sciences, Inc. (NASDAQ:BLSI) today announced that it has appointed
William L.S. Guinness to its Board of Directors. "I am very pleased
that Billy Guinness has agreed to join our board," stated BLSI
chairman Peter Savas. "He is committed to the medical needs
targeted by our current programs in Parkinson's disease, tremor,
stroke and optic nerve injury. Equally important is his interest,
as well as his ability to contribute to our plans to strengthen
BLSI's product pipeline through strategic transactions with other
promising companies. Billy's corporate development and financial
skills along with his access to extensive international resources
and relationships adds critical capabilities to our board." "I am
extremely pleased to serve on the Board of BLSI, a company with an
unwavering commitment to developing sorely needed diagnostics and
therapeutics for the treatment of central nervous system
disorders," stated Guinness. "My tenure on the BLSI board was a
short one in 2003, but I have watched the Company with great
interest and I am impressed with the Company's progress led by the
current directors, officers and principal shareholders during the
past two years. The Company's vision and growth strategy is
compelling and I believe the Company has taken the appropriate
steps to position itself to participate in a selective
consolidation of the life science sector. I look forward to working
closely with BLSI to guide the Company's future development, growth
and value building efforts." Mr. Guinness has been Chairman of
Sibir Energy plc since 1999 and had additional roles with Pentex
Energy plc and Pentex Oil plc. Mr. Guinness has been involved with
various private venture capital operations, which cover areas as
diverse as metal manufacturing, general aviation, and fine art
consultancy. Mr. Guinness is also a director of a number of private
companies involved in a wide range of commercial activities. Mr.
Guinness previously served on the Company's Board of Directors from
June 30, 2003 to September 20, 2003. About BLSI: Boston Life
Sciences, Inc. (BLSI) is engaged in the research and clinical
development of diagnostic and therapeutic products for central
nervous system (CNS) disorders. ALTROPANE(R) molecular imaging
agent is in Phase III clinical trials for the diagnosis of
Parkinsonian Syndrome (PS) and a Phase II clinical trial for the
diagnosis of Attention Deficit Hyperactivity Disorder (ADHD). The
Company's research and pre-clinical CNS programs include Inosine
for the treatment of stroke, a DAT blocker for the treatment of
Parkinson's disease and a second generation technetium-based
molecular imaging agent for PS and ADHD. BLSI's current research
collaborations include Harvard Medical School and Children's
Hospital of Boston. Statements in this press release regarding
Boston Life Sciences' future performance including statements
regarding the Company's future product pipeline and future
strategic initiatives, including possible acquisitions of, or
investments in, businesses, technologies and products that are
complimentary to the Company's business, and any other statements
about management's future expectations, beliefs, goals, plans or
prospects constitute forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Boston
Life Sciences' actual results could differ materially from those
stated or implied in forward-looking statements due to a number of
factors, including those factors contained in Boston Life Sciences'
Quarterly Report on Form 10-Q for the year ended March 31, 2006
filed with the Securities and Exchange Commission under the section
"Risk Factors," as well as other documents that may be filed by
Boston Life Sciences from time to time with the Securities and
Exchange Commission. Forward-looking statements include statements
regarding Boston Life Sciences' expectations, beliefs, intentions
or strategies regarding the future and can be identified by
forward-looking words such as "anticipate", "believe", "could",
"estimate", "expect", "intend", "may", "should", "will", and
"would" or similar words. Boston Life Sciences assumes no
obligations to update the information in this press release.
Contact: Sharon Correia -- 508-497-2360 ext 224 Boston Life
Sciences, Inc. DATASOURCE: Boston Life Sciences, Inc. CONTACT:
Sharon Correia, +1-508-497-2360, ext. 224 of Boston Life Sciences,
Inc., Web site: http://www.bostonlifesciences.com/
Copyright
Boston Life Sciences (NASDAQ:BLSI)
Historical Stock Chart
From May 2024 to Jun 2024
Boston Life Sciences (NASDAQ:BLSI)
Historical Stock Chart
From Jun 2023 to Jun 2024
Real-Time news about Boston Life Sciences (MM) (NASDAQ): 0 recent articles
More Boston Life Sciences (MM) News Articles